BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31002126)

  • 1. SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation.
    Liu Y; Chen JB; Zhang M; Zhang XL; Meng JL; Zhou J; Hao ZY; Zhang L; Zu XB; Liang CZ
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2756-2767. PubMed ID: 31002126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-Inducible Kinase 2 Promotes Bladder Cancer Cell Proliferation, Migration and Invasion by Enhancing β-catenin/c-Myc Signaling Pathway.
    Chen JB; Zhang M; Zhang XL; Cui Y; Liu PH; Hu J; Li HH; Jin H; Liu LF; Chen MF; Chen HQ; Liang CZ; Zu XB
    J Cancer; 2018; 9(24):4774-4782. PubMed ID: 30588263
    [No Abstract]   [Full Text] [Related]  

  • 3. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.
    Campbell L; Al-Jayyoussi G; Gutteridge R; Gumbleton N; Griffiths R; Gumbleton S; Smith MW; Griffiths DF; Gumbleton M
    J Transl Med; 2013 Oct; 11():255. PubMed ID: 24119769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
    Zhu Q; Zhong AL; Hu H; Zhao JJ; Weng DS; Tang Y; Pan QZ; Zhou ZQ; Song MJ; Yang JY; He JY; Liu Y; Li M; Hu WM; Yang CP; Xiang T; Chen MY; Ma G; Guo L; Xia JC
    J Hematol Oncol; 2020 Jan; 13(1):2. PubMed ID: 31900208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRPM7 Regulates AKT/FOXO1-Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma.
    Zhao Z; Zhang M; Duan X; Chen Y; Li E; Luo L; Wu W; Peng Z; Qiu H; Zeng G
    Mol Cancer Res; 2018 Jun; 16(6):1013-1023. PubMed ID: 29545479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.
    Lin TC; Liu YP; Chan YC; Su CY; Lin YF; Hsu SL; Yang CS; Hsiao M
    J Pathol; 2015 Sep; 237(1):50-61. PubMed ID: 25925728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
    Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
    Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
    Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
    Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
    Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLEKHO1 knockdown inhibits RCC cell viability in vitro and in vivo, potentially by the Hippo and MAPK/JNK pathways.
    Yu Z; Li Q; Zhang G; Lv C; Dong Q; Fu C; Kong C; Zeng Y
    Int J Oncol; 2019 Jul; 55(1):81-92. PubMed ID: 31180521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of cohesion 1 homolog 2 facilitates cell aggressive behaviors and induces poor prognosis in renal cell carcinoma.
    Wang QL; Liu L
    J Clin Lab Anal; 2020 May; 34(5):e23163. PubMed ID: 31944408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway.
    Ha YS; Kim YY; Yu NH; Chun SY; Choi SH; Lee JN; Kim BS; Yoo ES; Kwon TG
    Investig Clin Urol; 2018 Jul; 59(4):263-274. PubMed ID: 29984342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation.
    Ding XF; Chen J; Ma HL; Liang Y; Wang YF; Zhang HT; Li X; Chen G
    Life Sci; 2022 Mar; 293():120320. PubMed ID: 35063466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
    Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
    Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.